SNGX vs. ARTL, ENSC, ZVSA, HILS, LIPO, CING, GNPX, THAR, SEEL, and CPHI
Should you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Artelo Biosciences (ARTL), Ensysce Biosciences (ENSC), ZyVersa Therapeutics (ZVSA), Hillstream BioPharma (HILS), Lipella Pharmaceuticals (LIPO), Cingulate (CING), Genprex (GNPX), Tharimmune (THAR), Seelos Therapeutics (SEEL), and China Pharma (CPHI). These companies are all part of the "pharmaceutical preparations" industry.
Artelo Biosciences (NASDAQ:ARTL) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
Soligenix received 241 more outperform votes than Artelo Biosciences when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 72.55% of users gave Artelo Biosciences an outperform vote.
In the previous week, Artelo Biosciences had 1 more articles in the media than Soligenix. MarketBeat recorded 3 mentions for Artelo Biosciences and 2 mentions for Soligenix. Soligenix's average media sentiment score of 0.33 beat Artelo Biosciences' score of -0.50 indicating that Artelo Biosciences is being referred to more favorably in the media.
Artelo Biosciences has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.
0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 6.9% of Artelo Biosciences shares are owned by insiders. Comparatively, 1.4% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Artelo Biosciences currently has a consensus price target of $5.00, indicating a potential upside of 273.13%. Soligenix has a consensus price target of $3.00, indicating a potential upside of 602.58%. Given Artelo Biosciences' higher probable upside, analysts plainly believe Soligenix is more favorable than Artelo Biosciences.
Artelo Biosciences has a net margin of 0.00% compared to Artelo Biosciences' net margin of -731.94%. Soligenix's return on equity of -61.68% beat Artelo Biosciences' return on equity.
Soligenix has higher revenue and earnings than Artelo Biosciences. Soligenix is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Soligenix beats Artelo Biosciences on 9 of the 16 factors compared between the two stocks.
Get Soligenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soligenix Competitors List
Related Companies and Tools
